Molecular insights from structural dynamics of HER2-inhibitor complexes pave the way for new breast cancer drugs.

Abstract

The human epidermal growth factor receptor 2 (HER2) is closely associated with the development and progression of breast cancer, making it a critical target for therapeutic interventions. In this study, we employed a comprehensive computational drug discovery strategy to identify potential inhibitors of HER2. Our approach combined virtual screening, re-docking procedures, molecular dynamics (MD) simulations, and free energy landscape analysis using principal component analysis (PCA). From the extensive PubChem library, we initially screened 733 compounds for their binding potential to HER2, using docking scores as a primary filter. These scores ranged notably from -11.172 to -7.028 kcal/mol, indicating substantial binding capacities. Following this screening, we selected four promising compounds (PubChem CID 166029206, 166544027, 21031510, and 11712721) along with a control compound (70I) for in-depth analysis. Utilizing the Amber software suite for MD simulations, we conducted 200-nanosecond simulations to assess the interactions and binding efficiencies of these selected compounds with HER2. We analysed the molecular interactions through various parameters such as root mean square deviation (RMSD), root mean square fluctuation (RMSF), and hydrogen bond formation patterns, free binding energy calculations. The PCA-based free energy landscape analysis revealed that these compounds consistently occupied a distinct low-energy basin, indicating their high stability and strong binding affinity for the HER2. This detailed analysis provided insights into the stability and conformational dynamics of these potential inhibitors when bound to the HER2. Our findings pave the way for further experimental validation and development of these compounds as therapeutic agents in breast cancer treatment.